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Abstract
Methotrexate (MTX) is a systemic
immunosuppressant drug used for the treat-
ment of psoriasis and psoriatic arthritis.
Previous studies demonstrated a potential
association between psoriasis and diabetes
mellitus, obesity, atherosclerosis, hyperten-
sion, eventuating into metabolic syndrome.
This study aimed at exploring the glycemic
effects of MTX in psoriatic arthritis (PsA)
patients. In this prospective cross-sectional
study, 27 patients with PsA were evaluated.
The status of PsA and presence of accompa-
nying metabolic syndrome was determined
by standard criteria and indices. Blood indi-
cators including HbA1c, erythrocyte sedi-
mentation rate, fasting blood sugar, total cho-
lesterol, high-density lipoprotein, triglyc-
erides, and C-reactive protein were exam-
ined before and 12 weeks after MTX therapy.
There were no significant changes between
HbA1c levels before and after MTX therapy
in both genders (men: P=0.131, women:
P=0.803). In addition, HbA1c levels in PsA
patients with metabolic syndrome were not
different before and after treatment
(P=0.250). Finally, HbA1c levels did not
change in PsA patients without metabolic
syndrome before and after therapy
(P=0.506). MTX in PsA patients does not
appear to have hyperglycaemic effects in the
short-term and can be safely used in patients
with metabolic syndrome and diabetes.
Introduction
Psoriasis (PsO) is defined as a systemic,
inflammatory dermatologic disease which
affects approximately 2-3% of the global
population.1,2 Furthermore, psoriatic arthri-
tis (PsA) can develop in 7-48% of all PsO
subjects.3,4 Patients with PsO and/or PsA are
at a higher risk for development of other
chronic pathologic diseases, which can
complicate the management of these
patients.5-7 Previous studies have proved
that metabolic syndrome is related to a state
of chronic low-grade inflammation.8,9 The
underlying mechanism is partially
unknown, but a group of cytokines, includ-
ing tumor necrosis factor-α (TNF-α), have
been evidenced to reduce the activity of
insulin, contributing to insulin resistance.9-11
Unfortunately, there is limited data on asso-
ciation between metabolic syndrome and
rheumatological disorders, even though a
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few studies have reported an increased inci-
dence of metabolic syndrome in patients
with rheumatologic disease.12-14 Besides, a
few previous studies have indicated that
there is an association between the metabol-
ic syndrome and PsO.15,16 Additionally, epi-
demiological evidence has proposed that
systemic anti-inflammatory therapy might
be helpful to decrease the risk of cardiovas-
cular disease (CVD) in patients suffering
from psoriasis.17,18 Methotrexate (MTX) is
an anti-rheumatic drug with its cytotoxic,
anti-inflammatory and immune modulatory
activities often used in psoriasis treatment.
However, despite its use for the last 60
years, a close evaluation of its adverse
effects and related risk factors has not been
performed.19 In spite of growing concerns
about cumulative toxicity, there are no
detailed data for complications associated
with an increased cumulative dose of
MTX.20 Studies have demonstrated signifi-
cant reductions in CVD-related mortality in
patients treated with methotrexate.21 This
finding has been attributed to the potent
anti-inflammatory properties of methotrex-
ate.21,22 The aim of this study was to explore
the effects of short-term methotrexate ther-
apy on the blood levels of glucose and
HbA1c in patients having psoriasis.
Materials and Methods
Subjects
In this multicenter cross-sectional
study, 27 patients (aged 30-60 years) with
PsA from February 2016 to February 2018
were enrolled. The evaluation subjects
included the evidence of lifestyle factors
including smoking behavior, medical histo-
ry, taking medications, presence of diabetes
mellitus, hypertension, duration of disease,
comorbidities, and clinical examinations
which were obtained to discover the pres-
ence of PsA. Also, physical examination
included recording the number of tender
and swollen joints. To confirm the suspect
of PsA we also performed joints radiogram
and enthesis sonography. The diagnosis of
PsA was established by standard criteria for
psoriatic arthritis (CASPAR) with a score
>3 points.18 Additionally, other parameters
such as weight, height and waist circumfer-
ence, body mass index (BMI) (kg/m2) and
blood pressure were also measured. The sta-
tus of PsA was determined by the following
standard indexes: the Bath Ankylosing
Spondylitis Disease Activity Index,23
Disease Activity Score 2824 and the health
assessment questionnaire.25 Furthermore
metabolic syndrome was determined via the
International Diabetes Federation (IDF)
2004 and the National Cholesterol
Education Program Adult Panel III (NCEP
ATP III) (NCEP ATP III) 2001.26,27 All
patients were treated with oral methotrexate
(7.5 mg/kg) weekly for three months.
Before the collection of samples a written
informed consent was obtained from each
participant and ethical approval was granted
by the ethics committee of the Mazandaran
University of Medical Sciences, Pardis
Unit, Ramsar, Iran.
Inclusion and exclusion criteria
In this study, PsA was diagnosed and
confirmed by expert rheumatologists based
on the CASPAR.28 Subjects with other
inflammatory rheumatic diseases, myocar-
dial infarction (MI), stroke, hyper-gly-
caemic status different from diabetes melli-
tus type 2 e.g. hyperthyroidism and hyper-
glicaemic, renal insufficiency, lung or liver
or retroperitoneal fibrosis as well as patients
who took anti-inflammatory drugs
(NSAIDs or corticosteroids) were excluded
from the study.
Blood analysis
Following serum sampling, they were
kept at -80ºC until further processing. The
HbA1c and erythrocyte sedimentation rate
were primarily measured. Also, the serum
concentrations of fasting blood sugar
(FBS), total cholesterol, high-density
lipoprotein cholesterol (HDL), triglycerides
and C-reactive protein were measured using
an automated analyzer (Model 912, Hitachi,
Japan). All these parameters were examined
before and after 12 weeks of treatment with
methotrexate.
Statistical analysis
Data was expressed as mean ± standard
deviation (SD). Statistical analysis was con-
ducted using SPSS version 18 (SPSS, Inc,
Chicago, IL, USA). Differences were eval-
uated with the paired t test and chi-square
test. The normality of data was checked
using the one-sample Kolmogorov–
Smirnov Test. The significant level of dif-
ferences was set at 0.05.
Results
Inclusion criteria were met by 35
patients. Among these, 27 patients contin-
ued the study with the mean age of
43.22±8.9. Nine (33.33%) patients were
female and 18 (66.66%) were male.
Demographic data and clinical features of
patients before and after treatment are
shown in Table 1. Hyperlipidemia was pres-
ent in 7 (25.93%) patients at baseline for
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Table 1. Demographic and clinical features of the study patients.
Variation                                    Patients with PsA before treatment n=27           Patients with PsA after treatment n=27       P value
Age (years)                                                                                  43.22±8.9                                                                                             -                                                           -
Gender                                                                                                   
       Men N (%)                                                                             18 (66.7)                                                                                              -                                                           -
       Women N (%)                                                                        9 (33.3)                                                                                               -                                                           -
History of diabetes N (%)                                                          2 (10.0)                                                                                               -                                                           -
History of stroke N (%)                                                             10 (35.0)                                                                                              -                                                           -
History of Hyperlipidemia N (%)                                              7 (20.0)                                                                                               -                                                           -
FBS (mg/dL)                                                                               103.2±30.2                                                                                   101.3±22.8                                               0624
Total cholesterol (mg/dL)                                                       165.7±26.9                                                                                   166.5±33.2                                              0.881
HDL (mg/dL)                                                                                39.6±7.7                                                                                       42.8±6.2                                                0.005
LDL (mg/dL)                                                                                98.7±22.7                                                                                    104.6±22.7                                              0.059
CRP                                                                                            100% negative                                                                             100% negative                                            0.21
ESR (mm/hour)                                                                          24.2±17.9                                                                                     23.5±17.6                                               0.722
PsA, psoriatic arthritis patients; FBS, fasting blood sugar; HDL, high-density lipoprotein cholesterol; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
which 5 (18.52%) patients were using med-
ications. Family history of stroke was pres-
ent in 10 (37%) patients. In this study, 7
(25.93%) patients had a normal weight, 10
(37%) patients were overweight, and the
other 10 patients were obese. HbA1c test
was taken before and after using methotrex-
ate. At baseline, 2 (7.41%) patients had dia-
betes while the rest were negative. There
were no significant differences between
HbA1c levels among genders before and
after treatment with methotrexate (men:
P=0.131, women: P=0.803) (Figure 1).
According to the NCEP, 20 (74.04%)
patients had the signs of metabolic syn-
drome while the other 7 (25.93%) did not.
However, according to IDF, 19 (70.37%)
patients showed the signs of metabolic syn-
drome and 8 (29.63%) patients didn’t.
Furthermore, based on the NCEP index,
HbA1c levels in PsA patients with metabol-
ic syndrome were 5.7±0.9% before and
5.9±0.9% after methotrexate therapy
(P=0.250). However, HbA1c levels in PsA
patients without metabolic syndrome were
5.6±0.4 % and 5.7±0.5% before and after
methotrexate therapy respectively
(P=0.506) (Figure 2).
Discussion
Several studies have proposed that
patients with PsA are at increased risk of
CVD, obesity, diabetes and fatty liver dis-
ease.29-31Additionally, previous reports have
indicated that HbA1c as the primary screen-
ing tool for glucose intolerance and the
major predictive factor for cardiovascular
events.32,33 In the present study, we prospec-
tively examined the influence of short-term
anti-psoriatic therapy with methotrexate on
HbA1c.The findings showed that there was
no significant alteration in the HbA1c levels
after 12 weeks of continuous treatment.
Previously, deRotte and Perdan-Pirkmajer
et al. demonstrated that MTX reduced
HbA1c concentrations in patients with RA
or PsA.33,34 However, in a retrospective
cohort study,  Wu et al. showed that PsO,
PsA, and RA patients under treatment with
TNF inhibitors associated with MTX dis-
played no significant differences in terms of
the HbA1c level.35 Solomon et al. reported
that there is a non-significantly lower risk
of incident diabetes mellitus within patients
suffering from PsA, PsO, or RA who were
treated with methotrexate without tumor
necrosis factor inhibitors or hydroxychloro-
quine. Nonetheless, in contrast to our study,
Solomon et al. did not determine levels of
HbA1C and FBS in their research.36
Furthermore, Gisondi et al. conducted a sur-
vey of two groups of psoriasis patients who
were newly treated with methotrexate and
demonstrated that there was no detected
changes in the FBS level.37 In a 24-week
retrospective study comparing TNF
inhibitor, efalizumab, and methotrexate
there was no significant alterations in FBS
in any of the groups.38 Cuchacovich et al.
examined 37 patients with RA treated with
methotrexate (mean 34.7 months), and
found no significant changes have been in
FBS.39 All these reports are consistent with
the results of our study. It appears that the
administration of methotrexate for treat-
ment of PsA does not have hyperglycaemic
effects and thus it can be used in PsA
patients with metabolic syndrome and dia-
betes. Moreover, the most important part of
controlling the chronic disorders is follow-
ing a healthy lifestyle along with proper
medication. In addition, regular screening
of diabetes by monitoring BMI, FBS levels,
blood pressure and cholesterol levels may
help early detection and management of
new-onset diabetes in PsA patients being
treated with methotrexate.
Conclusions
To conclude, the use of methotrexate
was not related to a significant alteration in
HbA1C or FBS levels in patients with PsA.
According to the data obtained in this study,
methotrexate can be used in the treatment of
PsA patients without the risk of developing
diabetes.
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Figure 1. The level of HbA1c based on the gender of psoriatic
arthritis patients. The results are presented as mean ± SEM.
Statistically significant differences between control and patients
(P<0.05).
Figure 2. The level of HbA1c based on the National Cholesterol
Education Program Adult Panel index in psoriatic arthritis
patients patients with and without metabolic syndrome. Results
are presented as mean ± SEM. Statistically significant differences
between control and patients (P<0.05).
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